Brief: FDA Advisory Panel Backs Icecure's Prosense Cryoablation For Early-Stage Low Risk Breast Cancer
08/11/2024 12:03
Nov 8 (Reuters) - Icecure Medical Ltd ICCM.O :
* FDA ADVISORY PANEL VOTES IN FAVOR OF ICECURE'S PROSENSE®
CRYOABLATION BENEFIT-RISK PROFILE IN EARLY-STAGE LOW RISK BREAST
CANCER
* ICECURE MEDICAL LTD - FDA DECISION ON MARKETING
AUTHORIZATION
EXPECTED IN Q1 OF 2025
Source text: ID:nPn5ZW0XYa
Further company coverage: ICCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Icecure Medical
See all newsIcecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Brief: Icecure Sio Petitions Nccn To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM